Abstracts tagged "Disease Activity and remission"

Abstract Number: 2448 • 2019 ACR/ARP Annual Meeting
Factors Associated with Discordance Between Patient and Rheumatologist Assessment of Disease Activity in Psoriatic Arthritis Considered in Remission
Marie Moly¹, Cédric Lukas ², Jacques Morel ¹, Bernard Combe ³ and Gaël Mouterde ⁴, ¹CHU Montpellier, Montpellier, France, ²Rheumatology department, CHU Montpellier, Univ Montpellier, Montpellier, France, ³CHU Montpellier, Montpellier University, Montpellier, France, ⁴CHU Montpellier and Univ Montpellier, Montpellier, France
Background/Purpose: Assessment of disease activity in psoriatic arthritis (PsA) requires evaluation of multiple aspects and can be difficult. Perception of disease activity by patient and…
Abstract Number: 1713 • 2018 ACR/ARHP Annual Meeting
Attainment of Low Disease Activity and Remission in SLE Patients Who Started with High Disease Activity in the Atacicept Phase IIb Address II Study and Its Long-Term Extension
Eric Morand¹, Joan T. Merrill², David A. Isenberg³, Amy H. Kao⁴, Cristina Vazquez-Mateo⁴, Stephen Wax⁵, Peter Chang⁵, Kishore Pudota⁴, Cynthia Aranow⁶ and Daniel J. Wallace⁷, ¹Monash University, Melbourne, Australia, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³University College London, London, United Kingdom, ⁴EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁵EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA, ⁶The Feinstein Institute for Medical Research, Manhasset, NY, ⁷Cedars-Sinai Medical Center/David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
Background/Purpose: Low disease activity (LDA) and remission are important goals in the treatment of patients (pts) with SLE.1,2 Lupus Low Disease Activity State (LLDAS) is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].